SGLT2 Inhibitors Cut Kidney Events in Nephrotic Proteinuria
A study found that SGLT2 inhibitors significantly reduce the risk of major adverse kidney events in adults with type 2 diabetes and nephrotic-range proteinuria. Compared to DPP-4 inhibitors, SGLT2 inhibitors were associated with lower rates of end-stage kidney disease and all-cause mortality. These findings support the kidney-protective potential of SGLT2 inhibitors in high-risk diabetic patients.
- ▪Initiating SGLT2 inhibitors was linked to a 25% lower risk for major adverse kidney events compared to DPP-4 inhibitors.
- ▪Participants using SGLT2 inhibitors had a lower risk for end-stage kidney disease and all-cause mortality.
- ▪The study included 2102 participants with a mean age of approximately 61 years.
Medscape files mainly under health. We currently carry 231 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | Medscape |
| Canonical URL | https://www.medscape.com/viewarticle/sglt2-inhibitors-cut-kidney-events-nephrotic-proteinuria-2026a1000ifu?src=rss |
| Publication time | Wed, 3 Jun 2026 06:27:41 EDT |
| Retrieval time | 2026-06-03T10:42:02.244Z |
| Last seen | 2026-06-03T10:42:02.244Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | imGYqOuPnNAQ |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
TOPLINE:Among adults with type 2 diabetes (T2D) and nephrotic-range proteinuria, an extremely high-risk phenotype, initiating SGLT2 inhibitors instead of DPP-4 inhibitors was associated with lower long-term risks for major adverse kidney events (MAKEs), end-stage kidney disease requiring dialysis, and death from any cause.METHODOLOGY:Although SGLT2 inhibitors have demonstrated clear cardiorenal benefits in major randomized trials, it remains uncertain whether those benefits apply across the full spectrum of diabetic kidney disease — especially in patients with nephrotic-range proteinuria who were underrepresented in trials.Researchers conducted a retrospective cohort study using a new-user, active-comparator target trial emulation design to compare the effect of initiating SGLT2…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
